Furthermore, the authors show that LepB is active on other Rab family members and they explain, based on the structure, how posttranslational modifications interfere with GAP activity through steric hindrance.
Overall, this manuscript describes an interesting structure that provides insight into the mechanism of a bacterial GAP and highlights the variety of mechanisms adopted by bacterial proteins to take control of host signalling processes. Furthermore, based on sequence conservation of Rab GTPases and the interface of Rab1b with LepB the authors suggest that LepB would also be active on other Rabs and subsequently show biochemically that this is indeed the case.
Specific points:
-Why is the GTPase assay shown in Figure 2D -The authors should label the structures shown in Figures 1B and C with the name of the protein so it is immediately obvious that one is looking at 2 different structures, not the same structure that has just been rotated.
-The authors speculate that there are unidentified eukaryotic RabGAPs that could function by a mechanism similar to LepB. That seems a bit of a throwaway comment that should be substantiated.
-Why did the authors express Rab1b-LepB as a fusion protein, but then cleave it? That's rather unusual. The authors should add a statement explaining the rationale behind.
-Please add the amino acid numbering of Rab1 above the alignment in Figure 3A .
-I'm not convinced that Figure 4 illustrates very well the point the authors try to make. They should zoom in on the residues being modified and show their environment in detail rather than showing an overall figure of the complex.
-The authors should check the angles of the P31 crystals.
-What do the authors mean on page 4 by "...found activity towards...., and presumably Rab10"? Without an explanation this doesn't make sense.
Referee #2:
Legionella pneumophila has developed as an important model system for understanding how intracellular pathogens are able to replicate within host cells. Legionella is able to do this by subverting membrane trafficking pathways and does this by modulating the activity of Rab GTPases, esp Rab1. LepB is the Legionella effector protein that inactivates Rab1. The authors have elucidated the mechanism for LepB action through two structure determinations (LepB GAP domain alone and LepB GAP domain+ Rab1), finding that LepB has a novel fold but, rather surprisingly given that is has no sequence similarity with other known GAPs, shares features seen in other GAPs for small GTPases: the Arginine finger and use (in-trans) of a Rab1 Gln residue.
The mechanism, perhaps also surprisingly, differs from cellular RabGAPs studied so far, the TBCdomain proteins, which supply the Gln residue in cis.The importance of the Arg finger and the Rab1 Gln residue for GTP hydrolysis is well supported by biochemical data.
The authors also find that LepB acts on other Rabs in vitro, some of which may localize to the Legionella replication compartment as well and whose modulation by LepB might then be important for Legionella replication.
This work is carefully done and will be of high interest to the microbiology and cell biology/membrane trafficking communities, and merits publication.
I have only two minor suggestions: (1) it may be helpful to explain for non-specialists why LepB+Rab1 crystallization was carried out with the addition of beryllium fluoride.
(2) it is important to mention in the abstract that the LepB mechanism conforms to that of classical GAPs (despite the novel fold), in addition to being atypical for RabGAPs.
Referee #3:
The manuscript by E. Mihai Gazdag presents a thorough biochemical and structural study of the Rab-specific GTPase-activating protein (GAP) LepB from Legionella pneumophila. The authors show that LepB adopts a novel protein fold and stimulates GTP hydrolysis by Rab1 in a manner distinct from GAPs belonging to the TBC family of proteins. They demonstrate that LepB has a broad substrate specificity and is able to activate GTP hydrolysis by Rab3, 8, 13 , and 35 in addition to its previously identified substrate, Rab1. Structure and GAP activity of LepB fit in with prior knowledge about the molecular mechanisms of L. pneumophila infectivity, in particular by explaining the biological effects of post-translational modifications of Rab GTPases by other Legionella enzymes (adenylylation by DrrA, phosphocholination by AnkX). In the way this study was planned, executed and presented in the manuscript, it is nearly flawless. The manuscript may be further improved by addressing two minor concerns:
1. In Table 1 , the Rab1b:LepB complex crystals are said to belong to space group P31. There is no such space group. The authors should check if they meant to refer to space group P3</sub>1</sub>. If so, the γ angle of the unit cell (next line) is 120{degree sign}, not 90{degree sign}. I suggest, however, to delete this line altogether; given the space group, crystallographers will know the angle, others will not care.
2. Judged by the R</sub>mrgd-F<sub> and the <I/σ(I)>, the diffraction data appear to be truncated to a lower resolution than the crystal provided. This is a pity, because at slightly higher resolution a catalytic water molecule positioned by LepB Q67 (see Fig. S2 ) might have been revealed, thus strengthening the argument presented by the authors concerning the role of this residue in catalysis. The authors may want justify the apparent truncation of the experimental data. We would like to thank the reviewers for the positive reception of our manuscript and for their constructive comments. According to the reviewers' suggestions we have now modified the manuscript with a special emphasis on improving the clarity of data presentation and interpretation.
We hope to fulfill the requirements listed by the referees.
Reviewer #1:
Many 
However, LepB does not provide a Gln in trans to support catalysis but instead uses Gln67 of Rab1b to position a water molecule for attack on the g-phosphate as observed previously for classical

GAPs, indicating that the mechanisms used by LepB and TBC-GAPs are clearly different.
Overall, this manuscript describes an interesting structure that provides insight into the mechanism of a bacterial GAP and highlights the variety of mechanisms adopted by bacterial proteins to take control of host signalling processes. Furthermore, based on sequence conservation of Rab GTPases and the interface of Rab1b with LepB the authors suggest that LepB would also be active on other
Rabs and subsequently show biochemically that this is indeed the case. Figure 2D that compares the GAP activity of TBC1D20 and
Specific comments: -Why is the GTPase assay shown in
LepB done with different concentrations of the GAP? That makes it impossible to compare their activities. And what about the inset? What do the authors mean by "...equivalent activities at a 1:50 ratio"?
We see the point of the referee and have now realized that our previous descriptions were not ideal for demonstrating the significance of the Rab1 cis-glutamine for the catalysis by LepB. The rational of Figure 2D was to compare the different catalytic mechanisms of LepB and TBC1D20 with respect to the cis-glutamine. However, demonstrating this clearly in one figure by showing fluorescence raw data is challenging since the catalytic activity of LepB is about 50 times higher than for TBC1D20.
In order to illustrate the significance of the cis-glutamine of Rab1 for the GTP-hydrolysis reaction by LepB but not TBC1D20 more clearly, we have now replaced Figure 2D : The previous depiction of fluorescence traces has been changed to a bar diagram in which the catalytic efficiencies of LepB and TBC1D20 are directly compared in dependence of the Rab1 cis-glutamine (see below). We have adjusted the figure legend for Figure 2D accordingly. Figure 2D : The cis-glutamine of Rab1b is important for GTP-hydrolysis by LepB, but not TBC1D20. The figures compares the catalytic activities (k cat /K M ) of LepB and TBC1D20 in dependence of wild type and the Q67A mutant of Rab1. The Q67R substitution affects catalysis by LepB (14400 x reduction) 293 times more severly than for TBC1D20 (49 x reduction).
-The authors should state in the main text what the SER mutations introduced were.
In agreement with the referee, we have now stated the SER-mutations in the main text of our manuscript. We have added the following sentence in the methods section under Cloning, Protein
Expression and Purification, on page 10:
"The predicted LepB point mutants (K457A, E458A, and K460A) were generated by site-directed mutagenesis." Indeed, this statement is rather speculative and cannot be substantiated. However, a long standing question has been why Rab proteins require TBC-domain GAPs that operate by a catalytic mechanism distinct from other small G-proteins. One potential hypothesis is that Rab-proteins contain uncharacterized structure or sequence elements which prohibit a GAP-mechanism similar to classical GAPs. However, the determination of the LepB-mechanism now clearly shows that in principal Rab-proteins can be deactivated by a classical GAP-mechanism. Thus, the existence of mammalian non-TBC-GAPs is conceivable, yet unsubstantiated. In order to raise the awareness of possibly other Rab-GAPs, we prefer to keep this statement in our manuscript. We have thus amended the manuscript to underscore the speculative nature of the comment: Due to the low affinity of the Rab1b-LepB complex, we were unable to generate and purify a protein complex with a 1:1 composition by gel filtration. Therefore, we constructed the fusion protein between LepB and Rab1 to ensure a 1:1 ratio after purification. The addition of catalytic amounts of protease to the highly concentrated fusion protein ensured the integrity of the protein complex. Both cleaved and uncleaved fusion proteins were used in crystallization screens, but only the cleaved fusion protein gave complex crystals.
To clarify this context we have added the following sentence into the section "Cloning, protein expression and purification" on page 11.
"The low affinity between Rab1 and LepB did not allow complex purification using gel filtration; therefore, the Rab1b 3-174 :LepB 317-618 K457A E458A K460A complex was purified as fusion protein in order to ensure an 1:1 protein ratio. Crystallization screens were performed with the fusion construct and a sample cleaved using catalytic amounts of PreScission protease. Crystals were only identified in conditions that led to cleavage of the linker." Figure 3A .
-Please add the amino acid numbering of Rab1 above the alignment in
According to the reviewer's suggestion we have added the amino acid numbering of Rab1 above the alignment in Figure 3A . We have additionally added the following sentence to the figure legend of helices. This explains the inhibitory potential of adenylylation for LepB-stimulated GTP-hydrolysis (Goody et al, 2012; Müller et al, 2010) . The phosphocholinated S76 R side chain could in principle be accommodated without clashes. However, the observed LepB-inhibition by Rab1-phosphocholination could also be due to electrostatic effects." helices. This explains the inhibitory potential of adenylylation for LepB-stimulated GTP-hydrolysis (Goody et al, 2012; Müller et al, 2010) . The phosphocholinated S76 R side chain could in principle be accommodated without clashes. However, the observed LepB-inhibition by Rab1-phosphocholination could also be due to electrostatic effects.
-The authors should check the angles of the P31 crystals.
The reviewer is correct in that the angles of the space group P3 1 are wrong and we therefore corrected the values in the Table 1 as follows: α = β = 90°, γ = 120°.
-What do the authors mean on page 4 by "...found activity towards...., and presumably Rab10"?
Without an explanation this doesn't make sense.
The reviewer has identified an error in our manuscript. We have previously speculated that Rab10 could be a substrate for LepB due to its sequence homology to Rab1 (similar to Rab3, Rab8, and Rab13). However, we were unable to test this hypothesis. We have now eliminated the any speculation about Rab10 from the manuscript. We have therefore changed the sentence on page 4 in the introductory section:
"Based on the complex structure and amino acid sequence alignments of various Rab proteins, we have further investigated the specificity of LepB. LepB also stimulates GTP hydrolysis on Rab3, Rab8, Rab13, and Rab35."
Reviewer #2:
Legionella (1) it may be helpful to explain for non-specialists why LepB+Rab1 crystallization was carried out with the addition of beryllium fluoride.
To clarify the presence of beryllium fluoride in the buffer conditions we have added the following sentence to out manuscript on page 12 in the section "Crystallization and Structure Determination":
"(Beryllium fluoride and GDP mimic GTP and therefore stabilize the Rab1:LepB complex)."
We appreciate the careful reading of our manuscript and agree with the referee about the consistency of the abstract. We therefore added the following sentence on page 2 in the Abstract section:
"We present the crystal structure of the Rab1b:LepB-complex together with a thorough biochemical analysis and show that the GAP-domain of LepB consists of a novel fold. LepB acts by an atypical
RabGAP-mechanism that is reminiscent of classical GAPs and therefore sets the protein apart from mammalian TBC-like GAPs."
Reviewer #3:
The manuscript by E. Mihai Gazdag presents a thorough biochemical and structural study of the given the space group, crystallographers will know the angle, others will not care.
We appreciate the careful reading of the manuscript. We have corrected this in our manuscript in The reviewer is right concerning the low Rmrgd-F values and the truncation of the experimental data at a lower resolution. We have now truncated the experimental data at a higher Rmrgd-F value and refined the complex structure with 0.1ºÅ higher resolution than earlier described. The resulting data collection and refinement statistics are listed in Table1 on page 25 of our manuscript. However, this still did not lead to detectable electron density for the attacking water molecule.
2nd Editorial Decision 27 November 2012
Thank you for the submission of your revised manuscript to our journal. Since my colleague Barbara is currently not in the office, I have taken over the handling of your manuscript in order to prevent you from losing time. We have received the enclosed report from referee 1 now and you will see that the referee is very positive about publication of your study in EMBO reports. I only noticed a few very minor issues that need to be fixed before we can proceed with the official acceptance of your manuscript.
I saw that the supplemental information contains "supplemental text", which is not possible. Only supplemental material, figures, figure legends and references can be included in the supplemental information. The text therefore needs to be taken out. You could integrate it into the main manuscript file as there is still some space in terms of main text length. I also noticed that the label D in figure 2 is missing while it appears in the figure legend. Finally, I saw that the accession number for the protein structure is only mentioned in table 1 (as far as I can see). It would be better if you could also mention it in the methods section to make it a little more visible.
If you prefer, you can send us the new manuscript text and supplemental information and figure 2 via email attachment and we will replace the existing files for you. I look forward to seeing the final version of your manuscript as soon as possible.
Yours sincerely, Editor EMBO Reports ________________ REFEREE REPORTS Referee #1:
The authors have satisfactorily addressed all the comments raised by the reviewers and the manuscript is now suitable for publication in EMBO Reports. This is a really nice story that will be of great interest to many researchers.
2nd Revision -authors' response 28 November 2012
Thank you very much for your message and for the positive result on the manuscript evaluation.
Also, thanks for suggesting the changes to the manuscript. In accordance with your comments, please find the amended files attached. We have made the following changes: -The previous supplementary text is now part of the Methods section (chapter "Cloning, Protein Expression and Purification").
- Figure 2 has been modified to contain label D as suggested.
-The PDB accession numbers are also mentioned now in the Methods section (at the end of chapter "Crystallization and Structure Determination"). I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports. Thank you for your contribution to our journal.
Yours sincerely, Editor EMBO Reports
